PD-1 inhibitors exert anti-tumor effects by blocking the interaction of PD-1 on T cells with the immune-suppressing ligand programmed cell death ligand 1 (PD-L1) on tumor cells. This evidence concerns the gene PDCD1 and neoplasm.